Browse CLCA2

Summary
SymbolCLCA2
Namechloride channel accessory 2
Aliases CLCRG2; chloride channel, calcium activated, family member 2; chloride channel regulator 2; CACC3; CaCC-3; C ......
Chromosomal Location1p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein. Basal cell membrane; Single-pass type I membrane protein. Cell junction.; SUBCELLULAR LOCATION: Calcium-activated chloride channel regulator 2, 109 kDa form: Secreted. Note=Remains associated to the 35 kDa form until an unidentified event triggers the release.
Domain PF08434 Calcium-activated chloride channel
Function

Plays a role in modulating chloride current across the plasma membrane in a calcium-dependent manner, and cell adhesion. Involved in basal cell adhesion and/or stratification of squamous epithelia. May act as a tumor suppressor in breast and colorectal cancer. Plays a key role for cell adhesion in the beginning stages of lung metastasis via the binding to ITGB4.

> Gene Ontology
 
Biological Process GO:0006820 anion transport
GO:0006821 chloride transport
GO:0015698 inorganic anion transport
GO:0098656 anion transmembrane transport
GO:0098661 inorganic anion transmembrane transport
GO:1902476 chloride transmembrane transport
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0005216 ion channel activity
GO:0005229 intracellular calcium activated chloride channel activity
GO:0005253 anion channel activity
GO:0005254 chloride channel activity
GO:0008237 metallopeptidase activity
GO:0008509 anion transmembrane transporter activity
GO:0015103 inorganic anion transmembrane transporter activity
GO:0015108 chloride transmembrane transporter activity
GO:0015267 channel activity
GO:0015276 ligand-gated ion channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022834 ligand-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0022839 ion gated channel activity
GO:0061778 intracellular chloride channel activity
Cellular Component GO:0009925 basal plasma membrane
GO:0016323 basolateral plasma membrane
GO:0045178 basal part of cell
> KEGG and Reactome Pathway
 
KEGG hsa04972 Pancreatic secretion
Reactome R-HSA-983712: Ion channel transport
R-HSA-2672351: Stimuli-sensing channels
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolCLCA2
Namechloride channel accessory 2
Aliases CLCRG2; chloride channel, calcium activated, family member 2; chloride channel regulator 2; CACC3; CaCC-3; C ......
Chromosomal Location1p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CLCA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCLCA2
Namechloride channel accessory 2
Aliases CLCRG2; chloride channel, calcium activated, family member 2; chloride channel regulator 2; CACC3; CaCC-3; C ......
Chromosomal Location1p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CLCA2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCLCA2
Namechloride channel accessory 2
Aliases CLCRG2; chloride channel, calcium activated, family member 2; chloride channel regulator 2; CACC3; CaCC-3; C ......
Chromosomal Location1p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CLCA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8190.212
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.020.985
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.420.121
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5540.475
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8280.61
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2160.904
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.2520.21
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.6580.255
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7230.65
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0660.875
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1820.774
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.9870.0404
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CLCA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.83.712.10.224
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161418.87.111.70.602
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCLCA2
Namechloride channel accessory 2
Aliases CLCRG2; chloride channel, calcium activated, family member 2; chloride channel regulator 2; CACC3; CaCC-3; C ......
Chromosomal Location1p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CLCA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCLCA2
Namechloride channel accessory 2
Aliases CLCRG2; chloride channel, calcium activated, family member 2; chloride channel regulator 2; CACC3; CaCC-3; C ......
Chromosomal Location1p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CLCA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CLCA2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCLCA2
Namechloride channel accessory 2
Aliases CLCRG2; chloride channel, calcium activated, family member 2; chloride channel regulator 2; CACC3; CaCC-3; C ......
Chromosomal Location1p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CLCA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCLCA2
Namechloride channel accessory 2
Aliases CLCRG2; chloride channel, calcium activated, family member 2; chloride channel regulator 2; CACC3; CaCC-3; C ......
Chromosomal Location1p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CLCA2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCLCA2
Namechloride channel accessory 2
Aliases CLCRG2; chloride channel, calcium activated, family member 2; chloride channel regulator 2; CACC3; CaCC-3; C ......
Chromosomal Location1p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CLCA2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCLCA2
Namechloride channel accessory 2
Aliases CLCRG2; chloride channel, calcium activated, family member 2; chloride channel regulator 2; CACC3; CaCC-3; C ......
Chromosomal Location1p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CLCA2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.